These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 16284877

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Association of intestinal oxalate-degrading bacteria with recurrent calcium kidney stone formation and hyperoxaluria: a case-control study.
    Tavasoli S, Alebouyeh M, Naji M, Shakiba Majd G, Shabani Nashtaei M, Broumandnia N, Basiri A.
    BJU Int; 2020 Jan; 125(1):133-143. PubMed ID: 31145528
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Oxalate-degrading bacteria of the human gut as probiotics in the management of kidney stone disease.
    Abratt VR, Reid SJ.
    Adv Appl Microbiol; 2010 Jan; 72():63-87. PubMed ID: 20602988
    [Abstract] [Full Text] [Related]

  • 5. A critical analysis of the role of gut Oxalobacter formigenes in oxalate stone disease.
    Siva S, Barrack ER, Reddy GP, Thamilselvan V, Thamilselvan S, Menon M, Bhandari M.
    BJU Int; 2009 Jan; 103(1):18-21. PubMed ID: 19021605
    [Abstract] [Full Text] [Related]

  • 6. [Oxalobacter formigenes--characteristics and role in development of calcium oxalate urolithiasis].
    Torzewska A.
    Postepy Hig Med Dosw (Online); 2013 Nov 27; 67():1144-53. PubMed ID: 24379255
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. In vitro anti-inflammatory activity of selected oxalate-degrading probiotic bacteria: potential applications in the prevention and treatment of hyperoxaluria.
    Giardina S, Scilironi C, Michelotti A, Samuele A, Borella F, Daglia M, Marzatico F.
    J Food Sci; 2014 Mar 27; 79(3):M384-90. PubMed ID: 24471378
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.
    Hoppe B, Niaudet P, Salomon R, Harambat J, Hulton SA, Van't Hoff W, Moochhala SH, Deschênes G, Lindner E, Sjögren A, Cochat P.
    Pediatr Nephrol; 2017 May 27; 32(5):781-790. PubMed ID: 27924398
    [Abstract] [Full Text] [Related]

  • 18. The management of patients with enteric hyperoxaluria.
    Asplin JR.
    Urolithiasis; 2016 Feb 27; 44(1):33-43. PubMed ID: 26645872
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter.
    Hatch M, Gjymishka A, Salido EC, Allison MJ, Freel RW.
    Am J Physiol Gastrointest Liver Physiol; 2011 Mar 27; 300(3):G461-9. PubMed ID: 21163900
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.